Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PTEN loss |
Therapy | Ipatasertib + Onvansertib |
Indication/Tumor Type | prostate cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | prostate cancer | sensitive | Ipatasertib + Onvansertib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with the combination of Ipatasertib (GDC-0068) and Onvansertib (PCM-075) resulted in greater tumor growth inhibition compared to either therapy alone in PTEN-deficient prostate cancer cell line xenograft models (PMID: 38894678). | 38894678 |
PubMed Id | Reference Title | Details |
---|---|---|
(38894678) | AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. | Full reference... |